Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING LLC
RANDOX LABORATORIES

Gastroenterologists View Tissue In Situ Using Confocal Laser Endomicroscope

By Labmedica International staff writers
Posted on 15 Dec 2011
The confocal laser endomicroscope allows physicians to examine a patient’s GI tissue at the cellular level in its natural environment. This results in fewer biopsies being sent to pathology labs.

The microscope is called Cellvizio and is manufactured by Mauna Kea Technologies (MKEA; Newtown, PA, USA), a French company with offices in the United States. Cellvizio is a miniature microscope that, once inserted into the GI tract, enables the physician to select cells for microscopic examination in order to make a more immediate decision regarding a diagnosis, as well as treatment.

The Cellvizio system was cleared by the Food and Drug Administration (FDA) and has received CE mark in Europe. The company’s second-generation system, the Cellvizio 100 series was cleared in Europe and the United States in 2011. Although this micro-miniature microscope allows gastroenterologists to evaluate individual cells and identify abnormal or malignant tissue, there will still be a need to collect a tissue biopsy for analysis of its DNA, RNA, and/or proteins. The complexity of those genetic tests and molecular diagnostics assays means that most of these tissue referrals will continue to be sent to pathologists.

One contributing technology that went into this micro-miniature microscope is a high-density chip capable of performing several functions within a tiny module. Essentially, the Cellivizio system is a focal probe threaded through a traditional endoscope.

Dangerous tissue can be identified during the initial diagnostic exam. This allows gastroenterologists to remove this tissue the same day, and then go back to ensure that all of the diseased tissue was removed. This new approach will be applied to gastrointestinal cancers and other GI diseases, including those of the colon, bile duct, pancreas, and esophagus.

The Cellvizo system has the potential to pull more testing away from the traditional anatomic pathology laboratory. Michael J. Cima, PhD, at the Massachusetts Institute of Technology (MIT; Cambridge, MA, USA), recognized that possibility when he stated that, by using these types of systems to look at tissue in situ, “we are going to bring the laboratory into the patient.”

Related Links:
Mauna Kea Technologies
Massachusetts Institute of Technology


77 ELEKTRONIKA
KARL HECHT GMBH & CO KG
DIASYS DIAGNOSTIC SYSTEMS

Channels

Genetic Tests

view channel

Padlock Probe Assay Rapidly Detects Cardiac Disease Gene Mutations

A recent paper described a novel next generation sequencing (NGS) assay for detecting cardiac disease gene mutations with improved accuracy, flexibility, turnaround time, and cost. By using double-stranded DNA probes (complementary long "padlock" probes or cLPPs), investigators at Stanford University (Palo Alto, CA,... Read more

Hematology

view channel
Image: Immunochemistry of bone marrow biopsy from an acute myeloid leukemia patient showing sheets of CD34 positive cells; corresponding bone marrow aspirate showed only 20% blasts (Photo courtesy of All India Institute of Medical Sciences).

Immunohistochemistry Assesses Early Response in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to prognosis and early response assessment has an established role as predictor of remission rate, and overall and disease-free survival.... Read more

Industry News

view channel

Partners to Develop and Commercialize Noninvasive Tests for Bladder Cancer

An agreement between a major European university medical center and a multinational biotechnology company was designed to promote commercialization and further development of a liquid biopsy test for the diagnosis of bladder cancer. The liquid biopsy test is based on bladder cancer DNA methylation biomarkers developed... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.